Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy in the clinic: whose risks?

Richard E Ashcroft1

  • 1Imperial College London, Medical Ethics Unit, 324 Reynolds Building, St Dunstan's Road, London, W6 8RP, UK. r.ashcroft@imperial.ac.uk

Trends in Biotechnology
|October 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethical and Information Governance Considerations for Promoting Digital Social Interventions in Primary Care.

Journal of medical Internet research·2023
Same author

Non-randomised feasibility study testing a primary care intervention to promote engagement in an online health community for adults with troublesome asthma: protocol.

BMJ open·2023
Same author

Ethics and Harm Reduction Approaches in Tobacco Control.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2020
Same author

Euthanasia and the nature of suffering in addiction.

Addiction (Abingdon, England)·2018
Same author

The eSexual Health Clinic system for management, prevention, and control of sexually transmitted infections: exploratory studies in people testing for Chlamydia trachomatis.

The Lancet. Public health·2017
Same author

Law and the perils of philosophical grafts.

Journal of medical ethics·2017
Same journal

Smart biomaterials: From responsiveness to closed-loop sensing and feedback.

Trends in biotechnology·2026
Same journal

Bacterial spores as a modular platform for the production of amyloids for materials.

Trends in biotechnology·2026
Same journal

The oriGen case and Mexico's regulatory blind spots in genomic biobanking.

Trends in biotechnology·2026
Same journal

A caspase-3-activated protein expression system for apoptosis visualization and apoptosis-pyroptosis conversion to boost antitumor activity.

Trends in biotechnology·2026
Same journal

Over 4 months of ethylene production using solid-state photosynthetic cell factories.

Trends in biotechnology·2026
Same journal

Closing the nitrogen loop in groundwater with biohybrid technologies.

Trends in biotechnology·2026
See all related articles

Gene therapy for X-linked severe combined immunodeficiency disorder (X-SCID) may be standard care, but carries leukemia risks. A patient-centered approach is crucial for licensing such curative, yet risky, therapies.

Area of Science:

  • Immunology
  • Genetics
  • Medical Ethics

Background:

  • Gene therapy for X-linked severe combined immunodeficiency disorder (X-SCID) is advancing.
  • This potentially curative treatment carries an unquantified risk of secondary leukemia.
  • Regulatory questions arise regarding the acceptable risk-benefit balance for fatal childhood diseases.

Purpose of the Study:

  • To evaluate the current status of gene therapy for X-SCID.
  • To explore the ethical and regulatory considerations of therapies with significant risks.
  • To advocate for a patient-centered approach in licensing life-saving treatments.

Main Methods:

  • Review of current clinical experience with X-SCID gene therapy.
  • Ethical analysis of risk-benefit assessment in medical regulation.
Keywords:
Biomedical and Behavioral ResearchGenetics and ReproductionLegal Approach

Related Experiment Videos

  • Discussion of regulatory frameworks and patient advocacy.

    • Main Results:

    • Gene therapy for X-SCID may be approaching standard of care status.
    • The risk of therapy-induced leukemia remains a significant concern.
    • A patient-centered ethical framework is proposed for regulatory decisions.

    Conclusions:

    • The potential for leukemia necessitates careful regulatory oversight for X-SCID gene therapy.
    • Prioritizing the perspectives of patients and parents is essential for ethical therapy licensing.
    • A rational, patient-focused basis for licensing curative therapies with inherent risks needs further development.